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BRIEF REPORT
Spironolactone for People Age 70 Years and
Older With Osteoarthritic Knee Pain:
A Proof-of-Concept Trial
MARION E. T. MCMURDO,1 DEEPA SUMUKADAS,1 PETER T. DONNAN,1 VERA CVORO,2
PETRA RAUCHHAUS,1 ISHBEL ARGO,1 HELEN WALDIE,1 ROBERTA LITTLEFORD,3
ALLAN D. STRUTHERS,1 AND MILES D. WITHAM1
Objective. To determine whether spironolactone could benefit older people with osteoarthritis (OA), based on a previ-
ous study showing that spironolactone improved quality of life.
Methods. This parallel-group, randomized, placebo-controlled, double-blind trial randomized community-dwelling
people ages ‡70 years with symptomatic knee OA to 12 weeks of 25 mg daily oral spironolactone or matching pla-
cebo. The primary outcome was between-group difference in change in Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) pain subscale scores. Secondary outcomes included WOMAC stiffness and physical
function subscores, EuroQol 5-domain (EQ-5D) 3L score, and mechanistic markers. Analysis was by intent to treat,
using mixed-model regression, adjusting for baseline values of test variables.
Results. A total of 421 people had eligibility assessed, and 86 were randomized. Mean6SD age was 776 5 years and 53
of 86 (62%) were women. Adherence to study medication was 99%, and all participants completed the 12-week assess-
ment. No significant improvement was seen in the WOMAC pain score (adjusted treatment effect 0.5 points [95% confi-
dence interval (95% CI) 20.3, 1.3]; P5 0.19). No improvement was seen in WOMAC stiffness score (0.2 points [95% CI
20.6, 1.1]; P50.58), WOMAC physical function score (0.0 points [95% CI 20.7, 0.8]; P5 0.98), or EQ-5D 3L score (0.04
points [95% CI 20.04, 0.12]; P5 0.34). Cortisol, matrix metalloproteinase 3, and urinary C-telopeptide of type II collagen
were not significantly different between groups. More minor adverse events were noted in the spironolactone group (47
versus 32), but no increase in death or hospitalization was evident.
Conclusion. Spironolactone did not improve symptoms, physical function, or health-related quality of life in older
people with knee OA.
Introduction
Osteoarthritis (OA) affects over half of the population ages
$60 years. Management aims to reduce pain, improve
function, and improve quality of life, while minimizing
the adverse effects of therapy (1). Unfortunately, an appre-
ciable proportion of patients with OA have an inadequate
response to existing analgesic treatments (2). Worse still,
many existing analgesics, including both opioids and non-
steroidal antiinflammatory drugs (NSAIDs), have frequent
and severe side effects, including confusion, constipation,
hypertension, fluid retention, worsening of heart failure
and renal impairment, and gastrointestinal hemorrhage
in the predominantly older population who have OA. In
addition, paracetamol, often viewed as the analgesic of
choice in later life because of its absence of side effects,
has recently been shown to be of questionable effective-
ness in osteoarthritic pain (3).
Fresh pharmacologic approaches are therefore urgently
required for older people with OA to relieve pain and
improve quality of life while minimizing adverse effects.
We identified spironolactone, a well-established medica-
tion that is an aldosterone antagonist, as a potential novel
approach for older people with OA. Spironolactone has a
range of antiinflammatory properties (4) of potential rele-
vance to the treatment of OA. There is a wealth of data
that aldosterone is proinflammatory, so that by blocking
aldosterone, spironolactone may beneficially affect in-
flammation and pain in OA. In a previous double-blind
trial in 120 functionally impaired people (mean age 75
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years) exploring whether spironolactone improved muscle
function, 25 mg spironolactone daily was associated with
a significant improvement in health-related quality of life
(EuroQol 5-domain [EQ-5D] utility score) relative to pla-
cebo of 0.10 (95% confidence interval [95% CI] 0.03, 0.18;
P5 0.006), an improvement that exceeded the minimum
clinically important difference for this measure (5). Of the
120 participants, 41% (49 of 120) had self-reported OA at
baseline. Subgroup analysis of the EQ-5D scores showed
that 35% of participants taking spironolactone reported a
reduction in pain/discomfort at 20 weeks, compared to
only 5% on placebo (P , 0.01). We therefore performed a
proof-of-concept trial of spironolactone in a population of
older people with well-defined knee OA. The trial was
designed to provide preliminary evidence about whether
spironolactone is more effective than placebo in reducing
symptoms of knee pain in older people with OA knee,
when given in addition to usual medication.
Participants and methods
Design and participants. The study was a randomized,
double-blind, placebo-controlled, parallel-group trial. We
studied community-dwelling people ages $70 years with
knee pain due to OA. Inclusion criteria were as follows:
symptomatic idiopathic knee OA according to American
College of Rheumatology clinical and radiographic criteria
(6), moderate or more severe pain at screening (a score $4
on the Western Ontario and McMaster Universities Osteo-
arthritis Index [WOMAC] pain subscale) in at least 2 of 5
WOMAC pain score items, and receipt of 1 or more analge-
sic agents at a therapeutic dose for at least 2 months.
Exclusion criteria included the following: clinical diagno-
sis of symptomatic heart failure; history of inflammatory
arthritis; already taking spironolactone or previous intol-
erance; objection to taking capsules made from animal-
sourced gelatin; taking prescribed or over-the-counter oral
NSAIDs or taking angiotensin-converting enzyme inhibi-
tors or angiotensin II receptor blockers, because of the
potential risk of renal impairment when combined with
spironolactone; supine systolic blood pressure (BP)
,100 mm Hg at screening; significant chronic kidney dis-
ease (estimated glomerular filtration rate [eGFR] ,40 ml/
minute); serum sodium,130 mmoles/liter; serum potassium
.5.0 mmoles/liter; symptomatic orthostatic hypotension at
screening; currently receiving a course of physiotherapy;
requires a wheelchair; participating in another study; known
contraindication to spironolactone therapy; or having a ter-
minal illness.
Participants were recruited from the community via
primary care, using the Scottish Primary Care Research
Network, and via articles in the local media about the re-
search, previous research participants, and the SHARE
National Health Service (NHS) Scotland health re-
search register (www.registerforshare.org). Recruitment
took place in 3 Scottish regions (Dundee, Angus, and Fife)
between November 2013 and November 2014. All interest-
ed potential participants underwent a telephone pre-
screen, and those who appeared likely to be eligible
attended the hospital for an in-person screen. Research
ethics approval was obtained from the West of Scotland
Research Ethics Committee (13/WS/0232). Clinical trials
authorization was obtained from the UK Medicines and
Healthcare Regulatory Authority (European Union Drug
Regulating Authorities Clinical Trials No. 2013-002638-
19). The trial was sponsored by the University of Dundee
and NHS Tayside, was registered at clinicaltrials.gov
(ISRCTN02046668), and managed by the UK Clinical
Research Network registered Tayside Clinical Trials Unit.
The protocol is available on request.
Intervention. Randomization of medication was per-
formed by an independent third party (Tayside Pharmace-
uticals) after the baseline assessments had been completed.
The randomization code was held by Tayside Pharmaceuti-
cals until after the end of the trial to preserve allocation
concealment. After successful screening for eligibility and
safety, participants were randomized (1:1 ratio) without
blocking or stratification, using sequentially numbered bot-
tles, either to 25 mg spironolactone daily for 12 weeks or to
a matching placebo. Participants, health care providers,
and researchers were therefore masked to treatment alloca-
tion. Participants were allowed to continue all their usual
medication throughout.
Primary and secondary outcome measures. Outcomes
were collected at baseline and 12 weeks by 1 of 2 research
nurses masked to treatment allocation. The primary out-
come was the between-group difference in change in
WOMAC pain subscale (5 items) between baseline and 12
weeks. The WOMAC is a patient-reported questionnaire
(7) that is a valid, reliable, and sensitive instrument rec-
ommended for use in clinical studies (8). WOMAC numer-
ical rating scale version 3.1 was administered face-to-face
(9). Scores were assessed on an 11-point Likert scale for
each subscale (range 0–10, where higher values indicate
worsening). Three subscores were created from the ques-
tions (pain: 5 questions; stiffness: 2 questions; physical func-
tion: 12 questions) as the mean value of all questions for
each subscore. The WOMAC stiffness subscale, the WOMAC
physical function subscale, and health-related quality of life
measured by EQ-5D 3L questionnaire were also recorded.
Other measurements. At 2, 6, and 12 weeks any changes
to medication were noted, and blood was taken for sodium,
potassium, creatinine, eGFR, and magnesium. The 2- and
6-week blood samples were taken in the participants’
homes. Blood samples were analyzed in the Department of
Biochemical Medicine at Ninewells Hospital, Dundee,
Scotland.
Serum matrix metalloproteinase 3 (MMP-3), morning
serum cortisol level, and urinary C-telopeptides of type II
collagen (CTX-II), a marker for type II collagen degradation
Significance & Innovations
 Exploration of novel pharmacologic mechanism.
 Target population of older people (mean age 77
years).
 High adherence and completion rates.
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and osteophyte burden, were measured at baseline and 12
weeks in the Immunoassay Core Laboratory at Dundee
Medical School, using enzyme-linked immunosorbent
assay kits with intra-assay coefficients of 6%, 7.6%, and
12%, respectively. These biomarkers were measured for
explanatory purposes with the potential to elucidate the
mechanism of spironolactone on symptoms.
Statistical analysis. The purpose of this trial was proof
of concept to acquire preliminary data with which to
inform a larger definitive trial. The sample size was 80.
The selection of the sample size in such circumstances is,
to an extent, arbitrary. In anticipation of a dropout rate of
6.6% at 12 weeks (the dropout rate in our previous trial
was 6.6%), we aimed to recruit 86 participants for 80 to
complete. This sample size (40 participants randomized
to spironolactone, 40 participants randomized to placebo)
had 80% power to detect a between-group difference of
31% in WOMAC pain score. An improvement in WOMAC
pain score of 20% is regarded as being of moderate clinical
importance, according to the Osteoarthritis Research Soci-
ety International and Outcome Measures in Rheumatology
initiative, and this pilot study clearly would not have
enough power to detect this magnitude of difference (7).
Data were analyzed using the SAS 9.2 statistical pack-
age in accordance with a prespecified statistical analysis
plan. Analyses were performed only after all the data had
been entered and the database had been locked. Analyses
Expressed interest in trial and contacted for 
telephone prescreening (n = 421) 
204 from arcles in local media 
110 from Scosh Primary Care Research Network 
34 from SHARE research register 
32 from leaﬂets 
7 from previous research parcipants 
38 others
Failed prescreening (n = 312) 
42 taking an ACE inhibitor or ARB 
47 no knee pain 
42 no analgesia taken 
38 age <70 years 
25 bilateral knee replacements 
21 taking oral NSAIDs
Failed screening (n = 20) 
Did not meet ACR diagnosc criteria 9 
WOMAC pain score too low 5 
Taking oral NSAID or ARB 2 
Other 4
Aended screening visit (n = 109)
Baseline visit (n = 89)
12-week followup 
(n = 43)
Dropout (n = 5) 
Adverse event 3 
Paent choice 1 
Other 1 
Dropout (n = 3) 
Adverse event 2 
GP advice 1 
Randomized to 
spironolactone 
(n = 43)
Randomized to 
placebo 
(n = 43)
12-week followup 
(n = 43)
Not randomized (n = 3) 
due to intercurrent illness
Figure 1. Consolidated Standards of Reporting Trials flow diagram. SHARE5National
Health Service Scotland health research register; ACE5 angiotensin-converting
enzyme; ARB5 angiotensin II receptor blocker; NSAID5nonsteroidal antiinflamma-
tory drug; ACR5American College of Rheumatology; WOMAC5Western Ontario and
McMaster Universities Osteoarthritis Index; GP5 general practitioner.
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adjusting for differences in baseline data were performed.
Between-group changes in outcomes were analyzed using
intent-to-treat analysis. Missing data were handled by
multiple imputation, provided that the assumption of
missing at random was met. Mixed-model regression was
used to compare differences between the spironolactone
and the placebo groups, with adjustment for baseline
values.
Results
A total of 421 participants were assessed for eligibility.
Details of the recruitment and followup are given in the
Consolidated Standards of Reporting Trials flow diagram
(Figure 1). Of the 86 people randomized, 73% (63 of 86)
came from articles in the local media and primary care.
The median (range) adherence with medication, derived
from tablet counting, was 98% (58–106) in the spironolac-
tone group and 100% (60–100) in the placebo group. The
groups were well matched at baseline (Table 1), including
for analgesia use.
Medication was withdrawn from 8 participants, 5 in the
spironolactone group and 3 in the placebo group. The rea-
sons for withdrawal (n51 for each) in the spironolactone
group were rash and elevated creatinine level, elevated
creatinine level with low potassium, worsening pain that
initiated an oral NSAID, and personal reasons. Reasons
for withdrawal in the placebo group were elevated creati-
nine level, delirium, and an initiated course of physiother-
apy for knee pain. All 8 continued with study visits as per
intent to treat.
Primary and secondary outcomes. There was no between-
group difference in change in WOMAC pain scores (Table
2). Adjusted analyses also showed no significant difference
in change in WOMAC pain score between groups. The
amount of missing data on the WOMAC pain score was low
at 1.3% (11 of 860 items). Sensitivity analysis using worst-
case values and multiple imputation for missing values
did not alter the conclusions. There were no significant
between-group differences in changes in either unadjusted
or adjusted scores of WOMAC stiffness and physical func-
tion, EQ-5D 3L utility, and EQ-5D 3L visual analog scale
(VAS) scores (Table 2).
Other measurement results. Neither urine CTX-II or
serum MMP-3 changed significantly during the study in
either group (Table 2). Mean morning cortisol levels rose
more in the spironolactone group than in the placebo
group, a finding consistent with the known effects of spi-
ronolactone. However, the between-group difference in
change was not significant.
Safety blood samples showed small statistically but not
clinically significant increases in potassium (0.1 versus
20.1 mmoles/liter; P , 0.001) and creatinine levels (5
Table 1. Baseline characteristics*
Spironolactone
(n543)
Placebo
(n5 43)
Age, years 77.46 4.8 76.16 5.2
Weight, kg 76.36 15.6 81.3620.5
Women, no. (%) 26 (60) 27 (63)
Total no. medications 6.96 3.2 6.162.8
SIMD 1–5, no. (%) 19 (44) 20 (46)
Systolic blood pressure, mm Hg 1416 15 1486 15
Diastolic blood pressure, mm Hg 796 9 816 9
Analgesic medication, no. (%)
Nonopioid preparations 29 (67) 28 (65)
Opioids, weak† 16 (37) 17 (40)
Opioids, strong‡ 7 (16) 4 (9)
Drugs for neuropathic pain§ 5 (12) 5 (12)
Other analgesics¶ 7 (16) 9 (21)
WOMAC pain (0–10) 4.56 1.6 5.361.7
WOMAC stiffness (0–10) 5.56 2.0 6.261.6
WOMAC physical function (0–10) 4.86 1.7 5.261.8
EQ-5D utility 0.686 0.19 0.6060.28
EQ-5D VAS 67.96 16.5 70.4617.0
Changes in biomarkers
Urine CTX-II, mg/liter, median (IQR) 2.1 (1.2–4.7) 2.2 (1.2–4.0)
Serum MMP-3, ng/ml 256 16 25615
Morning cortisol, ng/ml 746 35 70629
* Values are mean6SD, unless indicated otherwise. SIMD5Scottish Index of Multiple Deprivation
(1–5 more deprived, 6–10 more affluent); WOMAC5Western Ontario and McMaster Universities Oste-
oarthritis Index; EQ-5D5EuroQol 5-domain; VAS5 visual analog scale; CTX-II5C-telopeptides of
type II collagen; IQR5 interquartile range; MMP-35matrix metalloproteinase 3.
† Codeine, dihydrocodeine.
‡ Oxycodone, buprenorphine, tramadol.
§ Amitriptyline, pregabalin, gabapentin.
¶ Paracetamol, topical nonsteroidal antiinflammatory drugs.
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versus 1 mmoles/liter; P 5 0.01) by 12 weeks in the spi-
ronolactone group, as would be expected, but no other
changes of significance. BP did not alter significantly in
the spironolactone group (systolic BP 22 versus 27 mm
Hg; P 5 0.1; diastolic BP 23 versus 24 mm Hg; P 5
0.5). During the trial, 5 participants began new analgesic
medication, 3 in the spironolactone group (n 5 1 weak
opioid, n 5 1 strong opioid, and n 5 1 other analgesic)
and 2 in the placebo group (n 5 2 other analgesic).
Adverse events and withdrawals. A total of 47 adverse
events occurred in the spironolactone group and 32 in the
placebo group. There were more gastrointestinal disorders
(10 versus 2) and infections (10 versus 6) in the spirono-
lactone group, but more musculoskeletal disorders (14
versus 9) in the placebo group. There were 5 hospitaliza-
tions, 3 in the spironolactone group (1 abdominal pain, 1
anal abscess, and 1 fracture of femoral neck) and 2 in the
placebo group (1 exacerbation of chronic obstructive pul-
monary disease and 1 delirium). There were no deaths.
Discussion
This double-blind study found that spironolactone did
not improve WOMAC pain score at 12 weeks compared to
placebo. This was a proof-of-concept study and deliber-
ately not powered to detect the minimum clinically
important between-group change, but was intended to
inform the development of a possible future larger trial.
However, there was no signal in the WOMAC pain scores
to indicate that spironolactone offered an advantage over
placebo; indeed, the 95% CI for the treatment effect did
not encompass a 20% improvement, denoting a moderate
treatment response compared to baseline. The lack of
change in the secondary outcomes and the biomarkers
(cortisol, MMP-3, and urinary CTX II) reinforce this nega-
tive finding.
A number of possible explanations for this null result
merit consideration. Ceiling effects on WOMAC ratings
would not explain the lack of treatment effect, as one of
the eligibility criteria was the need to score 4 or more on
at least 2 of the 5 WOMAC pain questions.
Nor does a between-group mismatch in analgesia use seem
a likely explanation for the result. The use of mild and strong
opioids at baseline was similar between the groups. Analgesic
medication altered little during the trial, although more peo-
ple in the spironolactone group began opioid medication.
The effect size in our placebo group was 0.53, comparable to
the 0.51 reported by Zhang et al (10) in a meta-analysis of the
placebo effect in 193 OA trials.
There are limitations as to the detail with which we
were able to phenotype participants’ disease; in particu-
lar, we were not able to ascertain the degree of chronic,
low-grade joint inflammation. Certain subgroups of pa-
tients with OA might exhibit greater responses to spirono-
lactone, such as those with a higher degree of chronic
synovitis or those with higher baseline turnover of colla-
gen matrix (11).
Possibly the 25-mg dose of spironolactone was insuffi-
cient. However this dose was used in our previous trial,
which significantly improved quality of life (using the
same EQ-5D 3L tool) (5), and the same dose is used to pro-
long life in heart failure (12); the 25-mg dose in heart fail-
ure has been shown to both increase cortisol levels (13)
and reduce markers of collagen turnover (14). A larger
dose would have increased the likelihood of adverse
effects, including raised potassium and creatinine levels,
and of gynecomastia in men. The 12-week duration of
treatment was selected for practical and pragmatic rea-
sons. A longer duration of therapy may have been neces-
sary, but the lack of any signal of efficacy in the current
study does not lend support to this idea. Furthermore, in
our original trial a signal of change in EQ-5D 3L score was
evident after 10 weeks of spironolactone, when the
Table 2. Unadjusted and adjusted changes at 12 weeks in outcomes and biomarker values by group*
Spironolactone Placebo
Mixed models‡
(n5 43)† (n5 43)† Unadjusted P Adjusted§ P
Primary outcomes
WOMAC pain¶ 21.0 (21.6, 20.4) 21.7 (22.3, 1.2) 20.01 (20.90, 0.88) 0.9 0.53 (20.27, 1.33) 0.19
WOMAC stiffness¶ 21.0 (21.6, 20.3) 21.4 (22.06, 20.73) 20.20 (21.18, 0.78) 0.69 0.24 (20.64, 1.13) 0.58
WOMAC physical
function¶
21.0 (21.5, 20.5) 21.1 (21.73, 20.50) 20.30 (21.19, 0.60) 0.51 0.01 (20.74, 0.76) 0.98
EQ-5D# 0.02 (20.05, 0.09) 0.03 (20.03, 0.10) 0.07 (20.02, 0.16) 0.13 0.04 (20.042, 0.12) 0.34
EQ-5D VAS# 0.5 (24.1, 5.0) 0.14 (25.23, 5.51) 22.19 (29.11, 4.73) 0.53 20.86 (26.90, 5.19) 0.78
Changes in biomarkers
Urine CTX-II, mg/liter 0.1 (20.8, 0.9) 20.03 (20.81, 0.75) 0.24 (20.93, 1.41) 0.68 0.21 (20.83, 1.24) 0.69
Serum MMP-3, ng/ml 1 (22, 5) 2.86 (21.34, 7.07) 21.44 (29.00, 6.11) 0.70 21.98 (27.32, 3.36) 0.46
Morning cortisol, ng/ml 13 (21, 27) 8.85 (22.56, 20.26) 8.15 (29.62, 25.95) 0.36 6.04 (210.66, 22.73) 0.47
* Values are mean (95% confidence interval), unless indicated otherwise. WOMAC5Western Ontario and McMaster Universities Osteoarthritis
Index; EQ-5D5EuroQol 5-domain; VAS5 visual analog scale; CTX-II5C-telopeptides of type II collagen; MMP-35matrix metalloproteinase 3.
† Difference to baseline.
‡ Difference between groups (spironolactone versus placebo).
§ Adjusted for recruitment site (Fife/Dundee) and baseline values. EQ-5D also adjusted for the presence of neuropathic drugs at baseline.
¶ Higher score5worse.
# Lower score5worse.
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between-group difference in change from baseline was
0.04 (20.03 to 1.11; P50.22) (5). The major difference
between the 2 study populations was self-reported physi-
cal disability in the former study, and specific selection
for symptomatic OA of the knee in this study. Study popu-
lations in both trials were similar in terms of baseline age,
sex, weight, social deprivation, EQ-5D utility score, and
EQ-5D VAS score.
The study has a number of strengths. Recruitment strat-
egies were efficient, with the target number of 86 partici-
pants randomized in the preplanned target 12-month
period. Adherence was exemplary, the dropout rate was
low, and treatment was well tolerated. This study con-
firms the safety of 25 mg spironolactone daily in this spe-
cific older population with OA. The mean age of
participants was 77 years, and there was no upper age lim-
it; this lack of a limit contrasts with around 25% of OA-
related trials, which did impose upper age limits (15), a
practice that is increasingly untenable. As most older peo-
ple are multimorbid, the prospect of a safe, established
medication with pleiotropic therapeutic effects is an
attractive one. Spironolactone improves outcomes in heart
failure and has effects on many cell types, independent of
its binding to mineralocorticoid receptors. One drug that
could safely treat more than one condition would be a
major advance in reducing treatment burden. This proof-
of-concept study found no evidence to support the further
evaluation of spironolactone for older people with knee
pain due to OA.
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